Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2019-11-27 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Zakończenie testów systemu BacterOMIC w Instytucie Gruźlicy Płuc w Warszawie - Content (PL)
Regulatory Filings Classification · 85% confidence The document is a report from the Management Board ("Zarząd") of Scope Fluidics S.A. detailing the results of external pre-validation tests for their BacterOMIC system conducted at a microbiology institute. It describes the testing methodology, objectives (confirming system functionality after changes, validating algorithms), and the successful outcome (over 90% agreement with the reference system Vitek2). This content focuses on the technical performance and validation of a product/technology, which aligns best with a general regulatory or informational report rather than a standard financial filing like 10-K, ER, or IR. Since it is a detailed report on a specific operational/technical matter that doesn't fit the specific categories like Audit (AR), Management Discussion (MDA), or Capital (CAP), it falls under the broad category of significant operational/regulatory information. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a detailed, non-standard operational report that isn't a core financial statement or management discussion, although it could arguably be seen as a form of 'Audit Report / Information' (AR) if the tests are considered a form of internal/regulatory stress test validation. However, since it is a specific operational update about product testing results, RNS serves as the best general regulatory/informational filing category when a more specific one is unavailable. The document is a full report, not an announcement of a report (ruling 2 does not apply).
2019-11-27 Polish
Deklaracje członków zarządu dotyczące udziału w ABB - Content (PL)
Director's Dealing Classification · 95% confidence The document discusses the intention of two executives (Piotr Garstecki and Marcin Izydorzak) to participate in an Accelerated Book Building (ABB) process initiated by TOTAL FIZ to sell a portion of its shares. It details the conditions, minimum transaction values (75,000 PLN), and the potential subsequent commitment by TOTAL FIZ to subscribe to a new share issue (Series F) at the same price. This activity directly relates to changes in share ownership, insider intentions regarding transactions, and capital structure adjustments (share issuance commitment). Since the core subject is the intention of directors/executives to acquire shares in a specific transaction (ABB) and the related capital commitment, it strongly aligns with insider dealings (DIRS) or capital/financing updates (CAP). Given that the primary focus is on the executives' intent to acquire shares in a transaction initiated by a major shareholder, and this involves personal transaction declarations by management, 'Director's Dealing' (DIRS) is a strong fit, although 'Capital/Financing Update' (CAP) is also relevant due to the linked share issuance commitment. However, the declaration of intent by the President and Board Member to participate in the sale/purchase process is a classic trigger for DIRS reporting. Since the text describes the personal transaction intentions of directors related to a share offering, DIRS is the most precise classification.
2019-11-25 Polish
Prof. Wilhelm Huck nowym członkiem Komitetu Doradczego - Content (PL)
Board/Management Information Classification · 98% confidence The document text announces that Professor Wilhelm Huck has joined the Advisory Committee of Scope Fluidics S.A. as of November 22, 2019, detailing his extensive background and how he will support the company's development and technology transfer. This content directly relates to changes in the company's advisory structure and the addition of a key expert, which falls under the category of Board/Management Information, as it concerns the composition of a body advising the Management Board.
2019-11-22 Polish
Prof. David Weitz nowym członkiem Komitetu Doradczego - Content (PL)
Board/Management Information Classification · 98% confidence The document text announces that Professor David Weitz has joined the Advisory Committee of Scope Fluidics S.A. as of November 15, 2019. This announcement details a change in the composition of an advisory body supporting the Management Board, specifically concerning the addition of a new expert member. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management (advisory roles often fall under this umbrella when related to strategic guidance). The document is short and focuses entirely on this personnel/advisory change.
2019-11-15 Polish
Zawarcie warunkowej umowy zobowiązującej do objęcia akcji Emitenta w ramach podwyższenia kapitału zakładowego. - Content (PL)
Capital/Financing Update Classification · 98% confidence The document discusses a conditional agreement ('Umowa') where TOTAL FIZ agrees to subscribe to new shares issued by Scope Fluidics S.A. as part of a capital increase ('podwyższenia kapitału zakładowego'). It also details a concurrent process where TOTAL FIZ intends to sell a portion of its existing shares through an accelerated book-building process ('przyspieszonej budowy księgi popytu') to existing shareholders. This entire transaction involves the issuance of new shares and changes to the capital structure, contingent on shareholder approval (AGM resolutions). This clearly falls under the category of company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-11-13 Polish
Ujawnienie opóźnionej informacji poufnej o uzgodnieniu z Total FIZ wstępnych warunków brzegowych transakcji podwyższenia kapitału zakładowego Spółki - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement by the Management Board ('Zarząd') of Scope Fluidics S.A. regarding the disclosure of previously delayed inside information ('Informacja Poufna'). The core content details an agreement with Total FIZ concerning a capital increase ('podwyższenia kapitału zakładowego') through the issuance of new shares and a concurrent accelerated book-building (ABB) process involving existing shares held by Total FIZ. This clearly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document explicitly mentions the use of funds for project development, confirming the financing nature of the announcement.
2019-11-13 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.